Table 1. Baseline Patient Characteristics (N=84).
| Variable | N (%) |
|---|---|
| Age | |
| Median (IQR) | 62.5 (55.8, 68.0) |
| Sex | |
| Male | 56 (67.0) |
| Prior Systemic RCC Therapy | |
| None | 73 (86.9) |
| IL-2 | 6 (7.1) |
| Other targeted agent | 5 (6.0) |
| Sunitinib Starting Dose | |
| 50 mg | 50 (59.5) |
| 37.5 mg | 4 (4.8) |
| 25 mg | 5 (6.0) |
| Other (Escalating Dose) | 25 (29.8) |
| Baseline Echo Parameters | |
| LVEF (%) Median (IQR) | 50.4 (45.1, 54.2) |
| GLS (%) Median (IQR) | -14.0 (−11.5, −15.5) |
| E/e’ Median (IQR) | 8.5 (6.9, 10.8) |
| Baseline Cardiac Biomarkers | |
| BNP (IQR), pg/ml | 31.7 (16.6, 64.8) |
| Baseline BMI | |
| Median (IQR), kg/m2 | 27.9 (24.2, 33.4) |
| Baseline Co-morbidities | |
| Hypertension | 46 (55.4) |
| Coronary artery disease | 8 (9.5) |
| Heart Failure | 3 (3.6) |
| Hyperlipidemia | 44 (52.4) |
| Diabetes Mellitus | 20 (23.8) |
| Tobacco Use | 7 (8.4) |
| Baseline Cardiac Medication Use | |
| Aspirin | 22 (26.2) |
| ACEI or ARB | 23 (27.4) |
| Beta Blocker | 22 (26.2) |
| Calcium Channel Blocker | 19 (22.6) |
| Diuretic | 14 (16.7) |
| Alpha Blocker | 3 (3.6) |
| Nitrate | 0 (0) |
| Statin | 27 (32.1) |
Abbreviations: IQR, interquartile range; RCC, renal cell carcinoma; IL-2, interleukin-2; LVEF, left ventricular ejection fraction; BNP, b-type natriuretic peptide; BMI, body mass index; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; Statin, HMG CoA reductase inhibitor.